Genelux (GNLX) vs vTv Therapeutics (VTVT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
vTv Therapeutics (VTVT) has outperformed Genelux (GNLX) over the past year, gaining 36.0% versus a loss of 47.4%. vTv Therapeutics is the larger company by market cap ($121.1 million vs $114.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GNLX | VTVT |
|---|---|---|
| Share price | $2.53 | $30.64 |
| Market cap | $114.47M | $121.13M |
| 1-day change | +1.20% | +1.85% |
| YTD return | -42.66% | -24.78% |
| 1-year return | -47.37% | +35.99% |
| 5-year return | — | -48.84% |
| EPS (TTM) | $-0.86 | $-0.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.54 | $44.00 |
| 52-week low | $2.29 | $19.50 |
| Distance from 52-week high | -70.36% | -30.37% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +644.27% | +78.59% |
| Average volume | 276.16K | 68.13K |
| Shares outstanding | 45.25M | 3.95M |
| Employees | 25 | 26 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VTVT has outperformed GNLX by 83.4 percentage points over the past year.
About Genelux
GNLX stock →Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
About vTv Therapeutics
VTVT stock →vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
GNLX vs VTVT FAQ
Which is bigger, Genelux or vTv Therapeutics?
vTv Therapeutics (VTVT) is larger, with a market capitalization of $121.13M compared with $114.47M for Genelux (GNLX).
Which stock has performed better over the past year, GNLX or VTVT?
VTVT returned +35.99% over the past 12 months, compared with -47.37% for GNLX (price return, excluding dividends). Past performance does not predict future results.
Are Genelux and vTv Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.